Denali Therapeutics (DNLI) Total Liabilities (2017 - 2026)
Denali Therapeutics (DNLI) posted quarterly Total Liabilities of $339.9 million for Q1 2026, up 128.66% year-over-year from $148.7 million in Q1 2025, and up 159.3% quarter-over-quarter from $131.1 million in Q4 2025.
Denali Therapeutics (DNLI) Total Liabilities (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Total Liabilities for 10 consecutive years, with $339.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 128.66% year-over-year to $339.9 million; the TTM figure through Mar 2026 stood at $339.9 million (up 128.66% YoY), while the FY2025 annual figure was $131.1 million, down 9.28% from the prior year.
- Total Liabilities improved to $339.9 million in Q1 2026 per DNLI's latest filing, from $131.1 million in the prior quarter.
- Across five years, Total Liabilities topped out at $442.6 million in Q1 2023 and bottomed at $115.5 million in Q2 2024.
- Historically, Total Liabilities has averaged $226.9 million across 5 years, with a median of $139.2 million in 2025.
- Annual changes were most pronounced in 2024 — Total Liabilities slumped 71.62% — and 2026, when it surged 128.66%.
- Denali Therapeutics' Total Liabilities stood at $417.8 million in 2022, then sank by 70.57% to $123.0 million in 2023, then gained by 17.51% to $144.5 million in 2024, then slipped by 9.28% to $131.1 million in 2025, then jumped by 159.3% to $339.9 million in 2026.
- Business Quant data shows DNLI's Total Liabilities at $339.9 million in Q1 2026, $131.1 million in Q4 2025, and $129.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | 322.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 322.78 Mn |
| Mar 31, 2026 | 339.93 Mn |
| Dec 31, 2025 | 131.09 Mn |
| Sep 30, 2025 | 129.42 Mn |
| Jun 30, 2025 | 139.19 Mn |
| Mar 31, 2025 | 148.66 Mn |
| Dec 31, 2024 | 144.50 Mn |
| Sep 30, 2024 | 135.52 Mn |
| Jun 30, 2024 | 115.51 Mn |
| Mar 31, 2024 | 125.62 Mn |
| Dec 31, 2023 | 122.96 Mn |
| Sep 30, 2023 | 118.45 Mn |
| Jun 30, 2023 | 118.91 Mn |
| Mar 31, 2023 | 442.64 Mn |
| Dec 31, 2022 | 417.81 Mn |
| Sep 30, 2022 | 416.30 Mn |
| Jun 30, 2022 | 408.01 Mn |
| Mar 31, 2022 | 402.93 Mn |
| Dec 31, 2021 | 441.87 Mn |
| Sep 30, 2021 | 437.69 Mn |